Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 16,113 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Completed Phase 3 Interventional Results available

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00735462
View directory record Official record
Conditions
Genital Warts
Interventions
2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 27, 2026, 9:27 AM EDT
Not listed Phase 2 Interventional

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer

NCT00003135
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
fluorouracil, pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 27, 2026, 9:27 AM EDT
Completed No phase listed Observational Results available

A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

NCT04721808
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
1,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 27, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

NCT03324425
View directory record Official record
Conditions
Breast Cancer Stage IV
Interventions
Simvastatin 80mg
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 27, 2026, 9:27 AM EDT
Active, not recruiting Not applicable Interventional Results available

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
8
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

NCT00565968
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
melphalan, sorafenib tosylate, gene expression analysis, protein expression analysis, western blotting, pharmacological study
Drug · Genetic · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168
View directory record Official record
Conditions
Keloid
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

NCT00902018
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Romiplostim, healthy controls
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Evaluation of Sun Protection Education for Kidney Transplant Recipients

NCT01844713
View directory record Official record
Conditions
Unspecified Complications of Kidney Transplant, Disorder Related to Renal Transplantation
Interventions
Workbook
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 27, 2026, 9:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

NCT00407979
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 27, 2026, 9:27 AM EDT
Terminated Not applicable Interventional Results available

Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention

NCT04092816
View directory record Official record
Conditions
Metastatic Breast Cancer, Parenting
Interventions
FAMILY Intervention
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 27, 2026, 9:27 AM EDT
Not listed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy

NCT00066547
View directory record Official record
Conditions
Breast Cancer
Interventions
monoclonal antibody HuHMFG1
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Not applicable Interventional

A Nutrition Intervention for Arthritis -3 (WCCR-ARTH3)

NCT03417648
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Plant-based diet, Supplement
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers

NCT00425178
View directory record Official record
Conditions
Chronic Wounds, Diabetes, Venous Stasis Ulcers
Interventions
FGF-1
Drug
Lead sponsor
Venturis Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Warren, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Recruiting Not applicable Interventional

Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers

NCT06938685
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, NeoThelium FT
Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Alexandria, Louisiana • Franklinton, Louisiana • Hammond, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Enrolling by invitation Phase 4 Interventional

Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover

NCT07230340
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Amnion-Intermediate-Chorion, Standard of Care (SOC)
Other · Procedure
Lead sponsor
Cellution Biologics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Active, not recruiting Phase 3 Interventional

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Boca Raton, Florida • Towson, Maryland • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

NCT02089087
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CFZ533, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
5
States / cities
Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 27, 2026, 9:27 AM EDT
Completed Not applicable Interventional Results available

Diet Interventions in Psoriatic Arthritis

NCT04180904
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Diet 1, Diet 2
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Active, not recruiting Not applicable Interventional

Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer

NCT04871516
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Boost, Therapeutic Surgical Procedure, Whole Breast Irradiation, Breast MRI
Other · Radiation · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes

NCT03718455
View directory record Official record
Conditions
Breast Cancer
Interventions
Axillary Magseed
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 27, 2026, 9:27 AM EDT
Recruiting Phase 2 Interventional

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

NCT07076485
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Loveland, Colorado • Jacksonville, Florida • Voorhees Township, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 9:27 AM EDT
Recruiting Phase 1 Interventional

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Budoprutug
Drug
Lead sponsor
Climb Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Allen, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 27, 2026, 9:27 AM EDT